3rd Quarter - Report — VAN HEUVELEN STRATEGIES, LLC for ALLERGAN PLC (FORMERLY KNOWN AS ACTAVIS) (2019)

Firm

VAN HEUVELEN STRATEGIES, LLC

Client

ALLERGAN PLC (FORMERLY KNOWN AS ACTAVIS)

Income

$50,000

Expenses

—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to implementation of the FDA user fee reauthorization bill Issues related to the Inter Partes Review (IPR) process S. 344, H.R. 990, Hatch-Waxman Integrity Act of 2019 S. 340, H.R. 965, CREATES Act of 2019 Issues related to drug compounding and counterfeit drugs S. 440, PACED Act

Lobbyist	Covered position, as disclosed
ROBERT VAN HEUVELEN	Chief of Staff to Senator Kent Conrad
STEPHEN DOUGLAS WARD	Chief of Staff to Senator Jeff Bingaman

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Bills named: H.R. 965 (116th), S. 440 (116th), S. 344 (116th), S. 340 (116th), H.R. 990 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.